These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
258 related articles for article (PubMed ID: 11550142)
1. Clinicopathologic implications of E-cadherin reactivity in patients with lobular carcinoma in situ of the breast. Goldstein NS; Kestin LL; Vicini FA Cancer; 2001 Aug; 92(4):738-47. PubMed ID: 11550142 [TBL] [Abstract][Full Text] [Related]
2. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: twelve-year observations concerning lobular carcinoma in situ. Fisher ER; Land SR; Fisher B; Mamounas E; Gilarski L; Wolmark N Cancer; 2004 Jan; 100(2):238-44. PubMed ID: 14716756 [TBL] [Abstract][Full Text] [Related]
3. Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988-2001. Li CI; Malone KE; Saltzman BS; Daling JR Cancer; 2006 May; 106(10):2104-12. PubMed ID: 16604564 [TBL] [Abstract][Full Text] [Related]
4. Expression of ERalpha and ERbeta in lobular carcinoma in situ. Middleton LP; Perkins GH; Tucker SL; Sahin AA; Singletary SE Histopathology; 2007 Jun; 50(7):875-80. PubMed ID: 17543077 [TBL] [Abstract][Full Text] [Related]
5. Is there a low-grade precursor pathway in breast cancer? King TA; Sakr RA; Muhsen S; Andrade VP; Giri D; Van Zee KJ; Morrow M Ann Surg Oncol; 2012 Apr; 19(4):1115-21. PubMed ID: 21935747 [TBL] [Abstract][Full Text] [Related]
6. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17. Five-year observations concerning lobular carcinoma in situ. Fisher ER; Costantino J; Fisher B; Palekar AS; Paik SM; Suarez CM; Wolmark N Cancer; 1996 Oct; 78(7):1403-16. PubMed ID: 8839545 [TBL] [Abstract][Full Text] [Related]
7. Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications. Acs G; Lawton TJ; Rebbeck TR; LiVolsi VA; Zhang PJ Am J Clin Pathol; 2001 Jan; 115(1):85-98. PubMed ID: 11190811 [TBL] [Abstract][Full Text] [Related]
8. The impact of lobular carcinoma in situ in association with invasive breast cancer on the rate of local recurrence in patients with early-stage breast cancer treated with breast-conserving therapy. Jolly S; Kestin LL; Goldstein NS; Vicini FA Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):365-71. PubMed ID: 16965988 [TBL] [Abstract][Full Text] [Related]
9. Lobular intraepithelial neoplasia [lobular carcinoma in situ] with comedo-type necrosis: A clinicopathologic study of 18 cases. Fadare O; Dadmanesh F; Alvarado-Cabrero I; Snyder R; Stephen Mitchell J; Tot T; Wang SA; Ghofrani M; Eusebi V; Martel M; Tavassoli FA Am J Surg Pathol; 2006 Nov; 30(11):1445-53. PubMed ID: 17063087 [TBL] [Abstract][Full Text] [Related]
10. Bilateral risk for subsequent breast cancer after lobular carcinoma-in-situ: analysis of surveillance, epidemiology, and end results data. Chuba PJ; Hamre MR; Yap J; Severson RK; Lucas D; Shamsa F; Aref A J Clin Oncol; 2005 Aug; 23(24):5534-41. PubMed ID: 16110014 [TBL] [Abstract][Full Text] [Related]
11. Bilateral and multifocal breast carcinoma. A clinical and autopsy study with special emphasis on carcinoma in situ. Ringberg A; Palmer B; Linell F; Rychterova V; Ljungberg O Eur J Surg Oncol; 1991 Feb; 17(1):20-9. PubMed ID: 1847343 [TBL] [Abstract][Full Text] [Related]
12. Clonality of lobular carcinoma in situ (LCIS) and metachronous invasive breast cancer. Aulmann S; Penzel R; Longerich T; Funke B; Schirmacher P; Sinn HP Breast Cancer Res Treat; 2008 Feb; 107(3):331-5. PubMed ID: 17380381 [TBL] [Abstract][Full Text] [Related]
13. Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy. Adepoju LJ; Symmans WF; Babiera GV; Singletary SE; Arun B; Sneige N; Pusztai L; Buchholz TA; Sahin A; Hunt KK; Meric-Bernstam F; Ross MI; Ames FC; Kuerer HM Cancer; 2006 Jan; 106(1):42-50. PubMed ID: 16333852 [TBL] [Abstract][Full Text] [Related]
14. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study. Ottesen GL APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968 [TBL] [Abstract][Full Text] [Related]
15. The florid subtype of lobular carcinoma in situ: marker or precursor for invasive lobular carcinoma? Bagaria SP; Shamonki J; Kinnaird M; Ray PS; Giuliano AE Ann Surg Oncol; 2011 Jul; 18(7):1845-51. PubMed ID: 21287281 [TBL] [Abstract][Full Text] [Related]
16. Is lobular carcinoma in situ as a component of breast carcinoma a risk factor for local failure after breast-conserving therapy? Results of a matched pair analysis. Ben-David MA; Kleer CG; Paramagul C; Griffith KA; Pierce LJ Cancer; 2006 Jan; 106(1):28-34. PubMed ID: 16329136 [TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic implications of E-cadherin reactivity in patients with lobular carcinoma in situ of the breast. Reis-Filho JS; Cancela Paredes J; Milanezi F; Schmitt FC Cancer; 2002 Apr; 94(7):2114-5; author reply 2115-6. PubMed ID: 11932917 [No Abstract] [Full Text] [Related]
18. Clinicopathologic analysis of breast lesions associated with multiple papillomas. Ali-Fehmi R; Carolin K; Wallis T; Visscher DW Hum Pathol; 2003 Mar; 34(3):234-9. PubMed ID: 12673557 [TBL] [Abstract][Full Text] [Related]
19. E-cadherin reactivity of 95 noninvasive ductal and lobular lesions of the breast. Implications for the interpretation of problematic lesions. Goldstein NS; Bassi D; Watts JC; Layfield LJ; Yaziji H; Gown AM Am J Clin Pathol; 2001 Apr; 115(4):534-42. PubMed ID: 11293901 [TBL] [Abstract][Full Text] [Related]
20. Factors predicting in-breast tumor recurrence after breast-conserving surgery. Mechera R; Viehl CT; Oertli D Breast Cancer Res Treat; 2009 Jul; 116(1):171-7. PubMed ID: 18815880 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]